Current treatment practice for essential thrombocythaemia in adults

Expert Opinion on Pharmacotherapy
Martin GriesshammerM Grünewald

Abstract

Essential thrombocythaemia (ET) is a relatively benign chronic myeloproliferative disorder that occurs primarily in middle-aged patients. Its clinical course is characterised by thomboembolic and, less frequently, by haemorrhagic complications. Life expectancy of ET is generally of normal length and progression to acute leukaemia is a rare event. About one third of all patients are asymptomatic at diagnosis and many of them remain without complications for years. Therefore, the main challenge for treating patients with ET is to select patients who will benefit from a cytoreductive or antiplatelet therapy, because it is doubtful whether the beneficial effects of therapy outweigh the potential hazards in all cases. For this reason a risk stratification in high and low risk ET patients is essential. The treatment of ET has evolved from alkylating agents to hydroxyurea (HU) or pipobroman and more recently to agents such as IFN-alpha and anagrelide. Aspirin as an antiplatelet therapy is also expected to play a part in the treatment of ET. HU is first-line therapy for elderly patients with high risk ET. In young ET patients without ET related complications and a platelet count < 1000 - 1500 x 10(9)/l abstention from cytoreductive the...Continue Reading

References

Jun 1, 1991·British Journal of Haematology·T C Pearson
Mar 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S CortelazzoT Barbui
Aug 1, 1990·Cancer·P FenauxF Bauters
Mar 15, 1988·Cancer·J J Lahuerta-PalaciosJ Montero-Castillo
Oct 1, 1986·Scandinavian Journal of Haematology·M G MazzucconiF Mandelli
Apr 27, 1995·The New England Journal of Medicine·S CortelazzoT Barbui
Jun 1, 1993·Neurology·J J MichielsH H van Vliet
Aug 1, 1993·Annals of Hematology·P J van Genderen, J J Michiels
Sep 1, 1996·Leukemia & Lymphoma·E LengfelderR Hehlmann
Jan 1, 1997·Seminars in Thrombosis and Hemostasis·M GriesshammerJ J Michiels
Jan 1, 1997·Seminars in Thrombosis and Hemostasis·M A Elliott, A Tefferi
May 23, 1998·Blood Reviews·S Willoughby, T C Pearson
Aug 14, 1998·Journal of the American Academy of Dermatology·G WeinlichP Fritsch
Dec 19, 1998·British Journal of Haematology·M RuggeriT Barbui
Jul 20, 1999·Archives of Dermatology·M E SirieixJ P Denoeux
Sep 1, 1999·British Journal of Haematology·M RuggeriT Barbui
Jan 20, 2000·Baillière's Clinical Haematology·M GriesshammerT Pearson
Mar 22, 2000·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·M L RandiA Girolami
Sep 1, 2000·The American Journal of Medicine·A TefferiM N Silverstein
Mar 16, 2001·Expert Opinion on Pharmacotherapy·S L Pescatore, C Lindley

❮ Previous
Next ❯

Citations

Jan 11, 2007·Orphanet Journal of Rare Diseases·Jean B Brière
Jul 6, 2005·International Journal of Obesity : Journal of the International Association for the Study of Obesity·J D DouketisD F Williamson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.